Lidove O - Search Results

1

[Enzyme therapy in Fabry disease: when scarcity of one enzyme illustrates the vulnerability of biotech].

Lidove O, Choukroun G, Bekri S, Viot G, Tsimaratos M, Joly D. Lidove O, et al. Presse Med. 2010 May;39(5):527-9. doi: 10.1016/j.lpm.2010.01.002. Epub 2010 Mar 2. Presse Med. 2010. PMID: 20194001 French. No abstract available.

2

[Fabry's disease in 2006: new treatment needs evaluation].

Lidove O, Bekri S, Andrès E. Lidove O, et al. Presse Med. 2006 Jun;35(6 Pt 1):933-5. doi: 10.1016/s0755-4982(06)74723-6. Presse Med. 2006. PMID: 16783249 French. No abstract available.

3

[Fabry disease: proposed guidelines from a French expert group for its diagnosis, treatment and follow-up].

Lidove O, Bekri S, Goizet C, Khau Van Kien A, Aractingi S, Knebelmann B, Choukroun G, Tsimaratos M, Redonnet-Vernhet I, Lacombe D, Jaussaud R. Lidove O, et al. Presse Med. 2007 Jul-Aug;36(7-8):1084-97. doi: 10.1016/j.lpm.2007.01.006. Epub 2007 Feb 2. Presse Med. 2007. PMID: 17276649 Review. French.

4

[What is the health insurance-Sécurité Sociale status for patients with Fabry disease?].

Lidove O, Choukroun G, Tsimaratos M, Jaussaud R; Conseil Scientifique de L'APMF (Association des Patients de la Maladie de Fabry). Lidove O, et al. Presse Med. 2008 Oct;37(10):1503-5. doi: 10.1016/j.lpm.2008.06.010. Epub 2008 Aug 30. Presse Med. 2008. PMID: 18757167 French. No abstract available.

5

[Treatment of Fabry disease: Successes, failures, and expectations].

Lidove O, Barbey F, Joly D. Lidove O, et al. Nephrol Ther. 2016 Apr;12 Suppl 1:S105-13. doi: 10.1016/j.nephro.2016.02.003. Epub 2016 Mar 8. Nephrol Ther. 2016. PMID: 26968478 Review. French.

6

Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature.

Lidove O, Joly D, Barbey F, Bekri S, Alexandra JF, Peigne V, Jaussaud R, Papo T. Lidove O, et al. Int J Clin Pract. 2007 Feb;61(2):293-302. doi: 10.1111/j.1742-1241.2006.01237.x. Int J Clin Pract. 2007. PMID: 17263716 Review.

7

Letter regarding Brouns et Al, Baptista et Al, and Wozniak et Al.

Lidove O, Joly D, Touzé E. Lidove O, et al. Stroke. 2011 Jan;42(1):e4-5; author reply e6-7. doi: 10.1161/STROKEAHA.110.591776. Epub 2010 Dec 9. Stroke. 2011. PMID: 21148443 No abstract available.

8

The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature.

Bekri S, Lidove O, Jaussaud R, Knebelmann B, Barbey F. Bekri S, et al. Among authors: lidove o. Cardiovasc Hematol Agents Med Chem. 2006 Oct;4(4):289-97. doi: 10.2174/187152506778520718. Cardiovasc Hematol Agents Med Chem. 2006. PMID: 17073606 Review.

9

Fabry disease in a geriatric population.

Barbey F, Joly D, Noel E, Drouineau O, Krayenbühl PA, Lidove O. Barbey F, et al. Among authors: lidove o. Clin Genet. 2015 Nov;88(5):499-501. doi: 10.1111/cge.12585. Epub 2015 Apr 10. Clin Genet. 2015. PMID: 25865499 No abstract available.

10

Renal disease in Fabry patients.

Grünfeld JP, Lidove O, Joly D, Barbey F. Grünfeld JP, et al. Among authors: lidove o. J Inherit Metab Dis. 2001;24 Suppl 2:71-4; discussion 65. doi: 10.1023/a:1012475908718. J Inherit Metab Dis. 2001. PMID: 11758682 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

202 results

Search Page

Filters